M&A / Deals BioMarin acquires Amicus Therapeutics for $4.8bn Pharmaceutical TechnologyBioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.Rare DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves AstraZeneca’s Saphnelo for SLENext: Boehringer/Zealand dual-acting drug causes 16.6% weight loss Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
